Market Place
Sourcing Support
FDA Confirms Paragraph IV Patent Litigation for Dalbavancin Hydrochloride
08 Aug 2023 //
FDA
Paladin Labs Launches of Xydalba (dalbavancin for injection) in Canada
18 Jan 2022 //
YAHOO FINANCE
Trial of existing antibiotic for treating Staphylococcus aureus bacteremia
27 Apr 2021 //
NIH
Global MRSA Drugs Market to Surpass US$ 1.3 Billion by 2026
24 Sep 2019 //
BUSINESSWIRE
Correvio Highlights FDA Acceptance of United Therapeutics` Trevyent NDA
11 Sep 2019 //
BIOSPACE
Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
04 Jun 2018 //
PRESS RELEASE
SMC OKs four new therapies for NHS use in Scotland
18 Jan 2017 //
PHARMATIMES
UK launch for Cardiome’s skin infections antibiotic
08 Dec 2016 //
PHARMATIMES
EMA approves Cardiome Pharma`s Xydalba single dose infusion
10 Aug 2016 //
PHARMABIZ
Angelini confirms commitment in Infection Control and Infectious Diseases Area
18 Apr 2016 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.